This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer

Welcome

Read time: 160 mins
Last updated:24th May 2022
Published:30th May 2020

Make the most of breakthrough treatments for early and advanced breast cancer.

  • Become an expert in navigating the treatment landscape for early and advanced breast cancer
  • Apply your knowledge to stratify and assess patients on the basis of their risk of recurrence
  • Identify patients with early and advanced breast cancer who may benefit from CDK4/6 inhibitor treatment

Dr Gregory Vidal, a medical oncologist at the West Cancer Centre and Research Institute and University of Tennessee, USA, explains why it is important for clinicians to keep on top of the current and future data for CDK4/6 inhibitors in breast cancer.

Our Experts

Throughout this Learning Zone, you will hear from some of our CDK4/6 inhibitor and breast cancer experts, including:

  • Dr Gregory Vidal is a haematologist/medical oncologist and clinical investigator at the West Cancer Centre and Research Institute and University of Tennessee, USA
  • Dr Laura Spring is a medical oncologist and clinical translational investigator at the Massachusetts General Hospital Cancer Centre and Harvard Medical School, USA
  • Dr Stephen Johnston is a Professor of Breast Cancer Medicine and Consultant Medical Oncologist, the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, UK
  • Professor Nadia Harbeck is Head of the Breast Cancer Centre at LMU University in Munich, Germany
Welcome: